QR-Code

Case report: Major pathologic response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with stage IIIA lung adenocarcinoma harboring BRAF V600E-mutation

Targeted therapy has achieved great success in advanced non-small lung cancer (NSCLC) with driver genes, and neoadjuvant-targeted therapy is increasingly being investigated. Although neoadjuvant-targeted therapy with EGFR-TKI and ALK-TKI showed good efficacy, there is no report of neoadjuvant-target...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Chaoyuan Liu, Min Lu, Yang Yang, Xiang Wang, Fang Ma, Xianling Liu
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2022-08-01
Schriftenreihe:Frontiers in Oncology
Schlagworte:
lung cancer
BRAF V600E mutation
neoadjuvant
targeted therapy
major pathologic response
Online-Zugang:https://www.frontiersin.org/articles/10.3389/fonc.2022.961539/full
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge